Cancer immunotherapy in older patients

Cancer Journal (United States)

Volumn 23, Issue 4, 2017, Pages 219-222

  Marrone, Kristen A ^a   Forde, Patrick M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; elderly; immune checkpoint inhibitors; immunosenescence

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; IMMUNOMODULATING AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; TUMOR MARKER;

AGED; AGING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; AGE; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 85026832921     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000268     Document Type: Review

References (54)

1. Cancer Stat Facts: Cancer of Any Site. 2014. Cancer Stat Facts: Cancer of Any Site. Available at: https://seer.cancer.gov/statfacts/html/all.html. Accessed April 1, 2017.
2. Levine ME. Modeling the rate of senescence: can estimated biological age predictmortalitymore accurately than chronological age? JGerontol A Biol Sci Med Sci. 2013; 68: 667-674.
3. Singh S, Bajorek B, Suzuki T , et al. Defining elderly in clinical practice guidelines for pharmacotherapy. Pharm Pract (Granada). 2014; 12: 12-489.
4. Orimo H, Ito H, Suzuki T , et al. Reviewing the definition of elderly. Geriatr Gerontol Int. 2006; 6: 149-158.
5. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004; 56: 163-184.
6. DePinho RA. The age of cancer. Nature. 2000; 408: 248-254.
7. Fulop T, Larbi A, Kotb R, et al. Aging, immunity, and cancer. Discov Med. 2011; 11: 537-550.
8. Vallejo AN. Immunological hurdles of ageing: indispensable research of the human model. Ageing Res Rev. 2011; 10: 315-318.
9. Miller RA. The aging immune system: primer and prospectus. Science. 1996; 273: 70-74.
10. Wick G, Grubeck-Loebenstein B. The aging immune system: primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol. 1997; 32: 401-413.
11. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-998.
12. Taverna G, Seveso M, Giusti G, et al. Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res. 2014; 2014: 478126.
13. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-Aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908: 244-254.
14. Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999; 108: 1-7.
15. Janeway CA Jr. How the immune system protects the host from infection. Microbes Infect. 2001; 3: 1167-1171.
16. Paganelli R, Quinti I, Fagiolo U, et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol. 1992; 90: 351-354.
17. Apoil PA, Puissant-Lubrano B, Congy-Jolivet N, et al. Influence of age, sex and HCMV-serostatus on blood lymphocyte subpopulations in healthy adults. Cell Immunol. 2017; 314: 42-53.
18. Krichevsky S, Pawelec G, Gural A, et al. Age related microsatellite instability in T cells from healthy individuals. Exp Gerontol. 2004; 39: 507-515.
19. Globerson A, Effros RB. Ageing of lymphocytes and lymphocytes in the aged. Immunol Today. 2000; 21: 515-521.
20. Shurin MR, Shurin GV, Chatta GS. Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol. 2007; 64: 90-105.
21. Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev. 2013; 12: 1069-1078.
22. Facchini A, Mariani E, Mariani AR, et al. Increased number of circulating Leu 11+ (CD 16) large granular lymphocytes and decreased NK activity during human ageing. Clin Exp Immunol. 1987; 68: 340-347.
23. Rukavina D, Laskarin G, Rubesa G, et al. Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. Blood. 1998; 92: 2410-2420.
24. Plackett TP, Boehmer ED, Faunce DE, et al. Aging and innate immune cells. J Leukoc Biol. 2004; 76: 291-299.
25. Nishioka T, Shimizu J, Iida R, et al. CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice. J Immunol. 2006; 176: 6586-6593.
26. Grizzle WE, Xu X, Zhang S, et al. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev. 2007; 128: 672-680.
27. Fulop T, Dupuis G, Witkowski JM, et al. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016; 68: 84-91.
28. Fulop T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013; 4: 271.
29. Wikby A, Johansson B, Olsson J, et al. Expansions of peripheral bloodCD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002; 37: 445-453.
30. Larbi A, Dupuis G, Khalil A, et al. Differential role of lipid rafts in the functions of CD4+ and CD8+ human T lymphocytes with aging. Cell Signal. 2006; 18: 1017-1030.
31. Goronzy JJ, Li G, Yu M, et al. Signaling pathways in aged T cells-A reflection of T cell differentiation, cell senescence and host environment. Semin Immunol. 2012; 24: 365-372.
32. Li G, Yu M, Lee WW, et al. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med. 2012; 18: 1518-1524.
33. Le Page A, Fortin C, Garneau H, et al. Downregulation of inhibitory SRC homology 2 domain-containing phosphatase-1 (SHP-1) leads to recovery of T cell responses in elderly. Cell Commun Signal. 2014; 12: 2.
34. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39: 1-10.
35. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264.
36. Ribas A. Tumor immunotherapy directed at PD-1. N Engl JMed. 2012; 366: 2517-2519.
37. Weber JS, DAngelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanomawho progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16: 375-384.
38. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23-34.
39. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372: 320-330.
40. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl JMed. 2015; 372: 2521-2532.
41. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373: 123-135.
42. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl JMed. 2015; 373: 1627-1639.
43. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387: 1540-1550.
44. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375: 1823-1833.
45. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl JMed. 2016; 375: 1856-1867.
46. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373: 1803-1813.
47. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389: 255-265.
48. Hodi FS, ODay SJ, McDermott DF, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
49. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124-128.
50. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371: 2189-2199.
51. Podolskiy DI, Lobanov AV, Kryukov GV, et al. Analysis of cancer genomes reveals basic features of human aging and its role in cancer development. Nat Commun. 2016; 7: 12157.
52. Meucci S, Keilholz U, Tinhofer I, et al. Mutational load and mutational patterns in relation to age in head and neck cancer. Oncotarget. 2016; 7: 69188-69199.
53. Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017; 7: 264-276.
54. Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog. 2013; 18: 573-583.